Vogenx (NASDAQ:VOGX) Raised to Hold at Wall Street Zen

Vogenx (NASDAQ:VOGX) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Vogenx Stock Performance

NASDAQ VOGX opened at $29.52 on Friday. Vogenx has a 1 year low of $12.95 and a 1 year high of $29.64.

Vogenx Company Profile

Vogenx Inc is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc is based in RALEIGH, NC.